Global Viral Vector Manufacturing CDMO Services Market Growth (Status and Outlook) 2026-2032

The global Viral Vector Manufacturing CDMO Services market size is predicted to grow from US$ 814 million in 2025 to US$ 3661 million in 2032; it is expected to grow at a CAGR of 24.4% from 2026 to 2032.

Viral Vector Manufacturing CDMO Services refer to providing professional viral vector production and development services to biopharmaceutical companies. These viral vectors are usually used in gene therapy, vaccine development, cell therapy and other fields. CDMO organizations are responsible for the design and optimization of viral vectors to large-scale production in accordance with GMP standards, ensuring the safety and effectiveness of the products, while strictly controlling the quality of each production link. These services provide key technical support for biopharmaceutical companies to help accelerate the development and commercialization of their products.

The Viral Vector Manufacturing CDMO Services market has emerged as a critical enabler of the rapidly growing gene therapy and advanced biologics sector, driven by the increasing demand for specialized production capabilities and accelerated time-to-market for innovative therapies. The market is characterized by high technological barriers, requiring expertise in viral vector design, process development, cGMP-compliant manufacturing, and quality assurance. Companies in this space are leveraging advanced bioprocessing technologies, automation, and artificial intelligence tools to improve yield, consistency, and scalability while maintaining regulatory compliance. Strategic partnerships between biotechnology firms and CDMOs are becoming increasingly common, allowing developers to outsource complex manufacturing tasks and focus on clinical development and commercialization. Overall, the market is marked by intense competition among specialized service providers, rapid technological innovation, and growing adoption of viral vector-based therapies across diverse therapeutic areas, positioning CDMOs as indispensable partners in the biopharmaceutical value chain.

LPI (LP Information)' newest research report, the “Viral Vector Manufacturing CDMO Services Industry Forecast” looks at past sales and reviews total world Viral Vector Manufacturing CDMO Services sales in 2025, providing a comprehensive analysis by region and market sector of projected Viral Vector Manufacturing CDMO Services sales for 2026 through 2032. With Viral Vector Manufacturing CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector Manufacturing CDMO Services industry.

This Insight Report provides a comprehensive analysis of the global Viral Vector Manufacturing CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector Manufacturing CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector Manufacturing CDMO Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector Manufacturing CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector Manufacturing CDMO Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector Manufacturing CDMO Services market by product type, application, key players and key regions and countries.

Segmentation by Type:

Adeno-associated Virus

Lentivirus

Adenovirus

HSV

Others

Segmentation by Development Scope:

Clinical stage CDMOs

Commercial stage CDMOs

End to end lifecycle CDMOs

Segmentation by Manufacturing Technology:

Adherent Cell Based

Suspension Based

Segmentation by Application:

Vaccine Development

Gene Therapy

Academic Scientific Research Institution

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Thermo Fisher Scientific

Lonza

Catalent

Charles River

Merck

SK pharmteco

Oxford Biomedica

AGC Biologics（MolMed）

Gene Universal

Polyplus (Sartorius)

CCRM

FUJIFILM Diosynth Biotechnologies

Biovian

Miltenyi Bioindustry

Aldevron

Takara Bio

Yposkesi

Genezen

Exthera

Flash Therapeutics

VIVEBiotech

FinVector

uBriGene

Eurogentec

VGXI

GenScript ProBio

EurekaBio

Obio Technology

GeneSail Biotech

VectorBuilder

WuXi ATU

Ubrigene

Porton Biologics

Pharmaron

PackGene Biotechnology

Hillgene

Asymchem

Please note: The report will take approximately 2 business days to prepare and deliver. Show more